LUMOS PHARMA, INC.

Analyst Reco. Lumos Pharma, Inc.

Equities

LUMO

US55028X1090

Real-time Estimate Cboe BZX Other stock markets 11:02:25 2024-04-23 am EDT			5-day change	1st Jan Change
2.855 ^USD	+6.53%		+12.10%	-11.16%

Mar. 07	Lumos Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 07	Transcript : Lumos Pharma, Inc., 2023 Earnings Call, Mar 07, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Trims Lumos Pharma Price Target to $16 From $17, Maintains Outperform Rating	Dec. 11	MT
Cantor Fitzgerald Adjusts Lumos Pharma's Price Target to $10 From $14, Keeps Overweight Rating	23-08-15	MT
Oppenheimer Adjusts Lumos Pharma Price Target to $17 From $18, Maintains Outperform Rating	23-08-10	MT
Jefferies Downgrades Lumos Pharma to Hold From Buy, Adjusts Price Target to $7 From $17	22-12-08	MT
Jefferies Downgrades Lumos Pharma to Hold From Buy With $7 Price Target	22-11-15	MT
Oppenheimer Initiates Coverage on Lumos Pharma With Outperform Rating, $20 Price Target	22-07-20	MT
LUMOS PHARMA : Roth Capital Adjusts Lumos Pharma's Price Target to $35 From $51, Maintains Buy Rating	21-07-22	MT
Lumas Pharma Shares Drop 12% After Treatment Period Extended	21-07-21	DJ
LUMOS PHARMA : HC Wainwright Adjusts Price Target on Lumos Pharma to $27 From $34, Maintains Buy Rating	21-07-21	MT
LUMOS PHARMA : JonesTrading Starts Lumos Pharma at Buy with $34 Price Target	21-04-13	MT
LUMOS PHARMA : Stifel Upgrades Lumos Pharma to Buy From Hold, Adjusts Price Target to $24 From $4	21-03-11	MT
LUMOS PHARMA : Cantor Fitzgerald Starts Lumos Pharma at Overweight with $32 Price Target	20-12-03	MT
LUMOS PHARMA : HC Wainwright Adjusts Lumos Pharma's Price Target to $34 From $33, Reiterates Buy Rating	20-11-23	MT
NewLink Genetics Corporation Announces Interim Phase 2 Data Demonstrate Robust Response Rate with Indoximod	17-04-04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer